Novo Nordisk layoffs begin across departments

Novo Nordisk, the maker of Wegovy and Ozempic, started notifying employees on October 14, 2025, about layoffs tied to a global restructuring plan announced the previous month ^[1]. By October 31, CEO Mike Doustdar said the company had notified impacted staff in "the vast majority" of the countries where it operates, though the pace of notifications differs from place to place because of local labor laws ^[1][2].

The cuts touch a wide range of departments, including human resources, clinical development, rare disease, medical and regulatory affairs, legal, ethics and compliance, marketing and sales, finance, and public affairs ^[1]. Reuters reported the total reduction at roughly 9,000 positions globally, part of a restructuring Doustdar launched last month as Novo faces intensifying competition from Eli Lilly in the weight-loss drug market ^[2]. Novo Nordisk has said the reorganization is meant to sharpen its focus on obesity and diabetes treatments while improving cost efficiency and commercial execution ^[1].

In a LinkedIn post, Doustdar wrote: "We have now notified impacted colleagues in the vast majority of our geographies, though the pace varies according to differences in local laws. In all our interactions, we have always sought to operate with transparency and respect" ^[1]. He also encouraged other employers to consider hiring laid-off staff, writing that people who see a former colleague with an "Open to Work" badge, or who receive a resume from someone who worked at Novo, should know "they are good people, who have a lot to offer" ^[1].

The announcement coincided with a stock move. Shares on the Copenhagen exchange closed 2.09% lower, at 315.95 krona, down from 322.70 krona in the prior session, according to one report ^[1]. That report did not specify whether this figure referred to Danish or Swedish krona, and no other financial detail from the sources clarifies which currency was meant.

Why it matters for patients

The sources do not describe any direct change to how Wegovy, Ozempic, or Rybelsus are made, shipped, or covered by insurance in the United States. The layoffs hit departments that touch drug development and regulatory work, including clinical development and medical and regulatory affairs, but neither source states that ongoing US clinical trials, supply, or patient support programs have been disrupted ^[1]. Whether patients calling manufacturer support lines, applying for savings cards, or waiting on new formulations could see any slowdown is not addressed in these reports and is not yet known.

What is documented is the company's stated reason for the cuts: sharpening its focus on obesity and diabetes drugs amid stiffer competition from Eli Lilly, whose tirzepatide products Zepbound and Mounjaro have gained ground in the same market ^[1][2]. For patients weighing GLP-1 options, that competitive backdrop is part of the environment shaping pricing, marketing, and possibly future drug development timelines at Novo Nordisk, though none of that is spelled out with specifics in the available sources.

What happens next

Doustdar's October 31 update said notifications were nearly complete in most countries, but the exact timeline for the remaining locations is not given in either source, and neither report specifies how many, if any, of the 9,000 affected roles are based in the United States ^[1][2]. Whether the restructuring will affect prescription supply, patient assistance programs, or the pace of new drug approvals in the US market is not addressed in these sources and remains unclear.